Back to Search
Start Over
Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator
- Source :
- Circulation. 128:944-953
- Publication Year :
- 2013
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2013.
-
Abstract
- Background— The most frequent complications associated with implantable cardioverter-defibrillators (ICDs) involve the transvenous leads. A subcutaneous implantable cardioverter-defibrillator (S-ICD) has been developed as an alternative system. This study evaluated the safety and effectiveness of the S-ICD System (Cameron Health/Boston Scientific) for the treatment of life-threatening ventricular arrhythmias (ventricular tachycardia/ventricular fibrillation). Methods and Results— This prospective, nonrandomized, multicenter trial included adult patients with a standard indication for an ICD, who neither required pacing nor had documented pace-terminable ventricular tachycardia. The primary safety end point was the 180-day S-ICD System complication-free rate compared with a prespecified performance goal of 79%. The primary effectiveness end point was the induced ventricular fibrillation conversion rate compared with a prespecified performance goal of 88%, with success defined as 2 consecutive ventricular fibrillation conversions of 4 attempts. Detection and conversion of spontaneous episodes were also evaluated. Device implantation was attempted in 321 of 330 enrolled patients, and 314 patients underwent successful implantation. The cohort was followed for a mean duration of 11 months. The study population was 74% male with a mean age of 52±16 years and mean left ventricular ejection fraction of 36±16%. A previous transvenous ICD had been implanted in 13%. Both primary end points were met: The 180-day system complication-free rate was 99%, and sensitivity analysis of the acute ventricular fibrillation conversion rate was >90% in the entire cohort. There were 38 discrete spontaneous episodes of ventricular tachycardia/ventricular fibrillation recorded in 21 patients (6.7%), all of which successfully converted. Forty-one patients (13.1%) received an inappropriate shock. Conclusions— The findings support the efficacy and safety of the S-ICD System for the treatment of life-threatening ventricular arrhythmias. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01064076.
- Subjects :
- Adult
Male
Tachycardia
medicine.medical_specialty
medicine.medical_treatment
Ventricular tachycardia
Cohort Studies
Physiology (medical)
Internal medicine
Multicenter trial
medicine
Humans
Prospective Studies
Prospective cohort study
Aged
Equipment Safety
Adult patients
business.industry
Middle Aged
Implantable cardioverter-defibrillator
medicine.disease
Defibrillators, Implantable
Treatment Outcome
Ventricular fibrillation
Tachycardia, Ventricular
Cardiology
Female
medicine.symptom
Cardiology and Cardiovascular Medicine
business
Follow-Up Studies
Cohort study
Subjects
Details
- ISSN :
- 15244539 and 00097322
- Volume :
- 128
- Database :
- OpenAIRE
- Journal :
- Circulation
- Accession number :
- edsair.doi.dedup.....aea9cb3a391d0188befdddbf13af7f14